Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Biocartis SA

Biocartis is a commercial stage molecular diagnostics company that develops diagnostics technology platforms for mult... read more Featured Products: More products

Download Mobile App




BRAF Mutation Detection Assay Earmarked for New PCR-based Molecular Diagnostics System

By LabMedica International staff writers
Posted on 28 Oct 2014
A fully automated real-time PCR based molecular diagnostics system and a dedicated assay that identifies cancers driven by the BRAF oncogene recently received European CE marking certification.

The recently launched Biocartis (Mechelen, Belgium) Idylla instrument is the backbone of the company's flagship molecular diagnostics system. More...
Along with Idylla, Biocartis also released the Idylla BRAF Mutation Test for detection of mutations in the BRAF oncogene.

The BRAF (v-Raf murine sarcoma viral oncogene homolog B1) gene encodes the protein serine/threonine-protein kinase B-Raf. About half of melanomas express the BRAFV600E mutation (at amino acid position number 600 on the B-Raf protein, the normal valine is replaced by glutamic acid). Inhibitors of B-Raf such as vemurafenib have been approved for the treatment of metastatic melanoma since August 2011. In addition to melanoma this mutation has been widely observed in papillary thyroid carcinoma and colorectal cancer.

The Idylla system is expected to establish a new standard for molecular diagnostic testing. The instrument's access on-demand design allows clinicians to initiate a new test at any given time, without the need for batching or for trained operators. The system’s short turnaround time—between 35 and 120 minutes—enables laboratories to report same-day results, significantly speeding up the treatment decision process. Idylla utilizes liquid-tight, disposable cartridges that reduce of risk of contamination and eliminate the necessity for separate pre- or post-PCR labs.

The BRAF Mutation Test is Idylla’s first oncology test and is designed to determine the most appropriate treatment for specific types of skin cancer. The assay can detect mutations directly from formalin-fixed paraffin-embedded (FFPE) tissue slices in about 90 minutes. This direct processing of FFPE tissue slices was cited as being unique for BRAF testing.

“Molecular testing plays a key role in the treatment decision process. It allows doctors to select specifically designed therapies based on the genetic profile of their patient,” said Rudi Pauwels, CEO of Biocartis. “Traditionally, molecular diagnostics involves a series of specialized, labor-intensive, and time-consuming steps. As a result, most labs do not perform these tests in-house, but send them to specialized labs where they are batched, often delaying treatment decisions. We are convinced that Idylla will completely transform the day-to-day practice in molecular labs, making molecular testing more straightforward than ever imagined. This will significantly speed up the diagnostic process and will enable doctors to make therapy decisions in a much shorter time frame. Ultimately, patients will receive a personalized therapy faster, ultimately improving treatment outcomes.”

Related Links:

Biocartis



New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Pipette
Accumax Smart Series
New
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Platelets sequester cfDNA during circulation (Murphy L. et al., Science, 2025; DOI: 10.1126/science.adp3971)

Platelets Could Improve Early and Minimally Invasive Detection of Cancer

Platelets are widely recognized for their role in blood clotting and scab formation, but they also play a crucial role in immune defense by detecting pathogens and recruiting immune cells.... Read more

Immunology

view channel
Image: The test could streamline clinical decision-making by identifying ideal candidates for immunotherapy upfront (Xiao, Y. et al. Cancer Biology & Medicine July 2025, 20250038)

Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option. Current biomarkers such as PD-L1 expression or tumor... Read more

Microbiology

view channel
Image: New diagnostics could predict a woman’s risk of a common sexually transmitted infection (Photo courtesy of 123RF)

New Markers Could Predict Risk of Severe Chlamydia Infection

Chlamydia trachomatis is a common sexually transmitted infection that can cause pelvic inflammatory disease, infertility, and other reproductive complications when it spreads to the upper genital tract.... Read more

Pathology

view channel
image: Researchers Marco Gustav (right) and MD Nic G. Reitsam (left) discuss the study data (Photo courtesy of Anja Stübner/EKFZ)

AI Model Simultaneously Detects Multiple Genetic Colorectal Cancer Markers in Tissue Samples

Colorectal cancer is a complex disease influenced by multiple genetic alterations. Traditionally, studies and diagnostic tools have focused on predicting only one mutation at a time, overlooking the interplay... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.